TJX Posts Strong Q3 Sales, Joins BellRing Brands, Bullish And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mostly fell, but TJX jumped 10.3% on strong sales and higher guidance; BellRing and other stocks also posted notable gains.

Last updated: 2026-11-18 19:25:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Windward Bio Group AG (WWB) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $23.37, with a market capitalization of $1.74B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $18.35 to $33.99. This page covers its latest market performance, valuation, price trends and company information.
$1.74B | |
$25.51 | |
$30.24 | |
$21.35 | |
$25.76 | |
189.57K | |
588.90K | |
-- | |
$33.99 | |
$18.35 | |
-- | |
2026-06-30 |
Windward Bio Group AG (WWB) is currently trading at $23.37 as of 2026-11-18 19:23:00, down 13.82% ($3.56) from the previous close of $25.76
During today's regular trading session, WWB has traded between $21.35 and $30.24, with a trading volume of 189.57K shares. The current price is near the lower end of today's range.
Over the past seven days, Windward Bio Group AG (WWB) moved from $28.50 to $23.37, representing a decline of 18.00% ($5.13).
The stock traded between $18.35 and $33.99 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 588.90 thousand shares, -- versus the previous seven-day period, indicating -- trading activity.
Position in Range: 32.1%
WWB is currently trading at $23.37, placing it 32.1% of the way from its 52-week low of $18.35 to its 52-week high of $33.99. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Windward Bio Group AG is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, COPD, and atopic dermatitis. Its flagship program is WIN378, a potentially novel, long-acting, anti-TSLP monoclonal antibody. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bi-specific, which has therapeutic application across immunological diseases.
| Exchange | NASDAQ |
| Company Website |
Latest news related to Windward Bio Group AG and WWB stock.
U.S. stocks mostly fell, but TJX jumped 10.3% on strong sales and higher guidance; BellRing and other stocks also posted notable gains.
U.S. stock futures fell as Aclaris plunged 21% after its dermatitis trial failed; Summit and other stocks also dropped in premarket trading.
Eligible investors can buy real shares of Windward Bio Group AG (WWB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to WWB, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between WWB shares and USD.
WWB Shares to USD
1.00 WWB shares = 23.37 USD
Calculations are estimates based on the latest available price and are for reference only.